Literature DB >> 6753912

Postoperative radiotherapy in rectosigmoid cancer Dukes' B and C: interim report from a randomized multicentre study.

I Balslev, M Pedersen, P S Teglbjaerg, F Hanberg-Sørensen, J Bone, N O Jacobsen, J Overgaard, A Sell, K Bertelsen, E Hage, L Hansen, O Kronborg, H Høstrup, B Nørgaard-Pedersen.   

Abstract

The design, and complications seen during the first 2 years, of a randomized trial of postoperative radiotherapy for rectosigmoid cancer Dukes' B and C are presented and discussed. It is concluded that the present complication rate-below 10% in 221 patients-permits continuation of the intake, which is planned to include 550 patients, to demonstrate a possible increase in crude 5-year survival by 15% (60-75% in Dukes' B and 25-40% in Dukes' C), on the basis of a 0·01 significance level and a probability that the experiment will be successful of 0·90.

Entities:  

Mesh：

Year:  1982        PMID： 6753912      PMCID： PMC2011200          DOI： 10.1038/bjc.1982.239

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  12 in total

1.  Radiation therapy: results and future possibilities.

Authors:  L L Gunderson
Journal:  Clin Gastroenterol       Date:  1976-09

2.  Surgical management of radiation injury to the small intestine.

Authors:  R W Swan; W C Fowler; R C Boronow
Journal:  Surg Gynecol Obstet       Date:  1976-03

3.  Preoperative radiotherapy for adenocarcinoma of the rectosigmoid.

Authors:  K R Stevens; C V Allen; W S Fletcher
Journal:  Cancer       Date:  1976-06       Impact factor: 6.860

4.  Effects of abdominal surgery on the development of radiation enteropathy.

Authors:  T LoIudice; D Baxter; J Balint
Journal:  Gastroenterology       Date:  1977-11       Impact factor: 22.682

5.  Major intestinal complications of radiotherapy.

Authors:  M Deitel; V Vasic
Journal:  Am J Gastroenterol       Date:  1979-07       Impact factor: 10.864

6.  Preoperative irradiation of operable adenocarcinoma of the rectum and rectosigmoid colon.

Authors:  B Roswit; G A Higgins; E W Humphrey; C D Robinette
Journal:  Radiology       Date:  1973-08       Impact factor: 11.105

7.  Rectal cancer: adjuvant radiation therapy.

Authors:  J P Green
Journal:  Front Radiat Ther Oncol       Date:  1980

8.  Post-operative radiotherapy for adenocarcinoma of the rectum and rectosigmoid.

Authors:  H R Withers; M M Romsdahl
Journal:  Int J Radiat Oncol Biol Phys       Date:  1977 Nov-Dec       Impact factor: 7.038

9.  Postoperative radiotherapy in carcinomas of the rectum and distal sigmoid colon.

Authors:  O A Mendiondo; C C Wang; J P Welch; G A Donaldson
Journal:  Radiology       Date:  1976-06       Impact factor: 11.105

10.  Operative management of radiation injuries of the intestinal tract.

Authors:  J C Russell; J P Welch
Journal:  Am J Surg       Date:  1979-04       Impact factor: 2.565
View more
  4 in total

1.  Do synchronous adenomas influence prognosis after radical surgery for colorectal carcinoma? A prospective study.

Authors:  O Kronborg; E Hage; C Fenger; E Deichgraeber
Journal:  Int J Colorectal Dis       Date:  1986-04       Impact factor: 2.571

2.  A regression analysis of prognostic factors after resection of Dukes' B and C carcinoma of the rectum and rectosigmoid. Does post-operative radiotherapy change the prognosis?

Authors:  S M Bentzen; I Balslev; M Pedersen; P S Teglbjaerg; F Hanberg-Soerensen; J Bone; N O Jacobsen; J Overgaard; A Sell; K Bertelsen
Journal:  Br J Cancer       Date:  1988-08       Impact factor: 7.640

3.  Adjuvant therapy in colorectal cancer.

Authors:  A K House
Journal:  J R Soc Med       Date:  1984-06       Impact factor: 18.000

4.  Time to loco-regional recurrence after resection of Dukes' B and C colorectal cancer with or without adjuvant postoperative radiotherapy. A multivariate regression analysis.

Authors:  S M Bentzen; I Balslev; M Pedersen; P S Teglbjaerg; F Hanberg-Sørensen; J Bone; N O Jacobsen; A Sell; J Overgaard; K Bertelsen
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.